Skip to main content
Fig. 1 | Asthma Research and Practice

Fig. 1

From: Once-daily fluticasone furoate/vilanterol versus twice daily combination therapies in asthma–mixed treatment comparisons of clinical efficacy

Fig. 1

Networks of study treatments, by outcome of interest (primary analysis population). a change from baseline in morning PEF. b change from baseline in FEV1. c annual rate of moderate/severe exacerbations. d AQLQ Total score. Note: All stated doses are mcg. Delivered doses are given for FF/VI at the strengths licenced in Europe for the treatment of asthma, and for BUD/FORM. For all other treatments, nominal doses are given. Connecting lines represent studies included in the model that directly compare the two treatments. The thickness of the line is proportional to the number of studies comparing the two treatments. BDP = beclomethasone dipropionate, BID = twice daily, BUD = budesonide, F = formoterol, FEV1 = forced expiratory volume in 1 s, FF = fluticasone furoate, FP = fluticasone propionate, HFA = hydrofluoroalkane, MMF = mometasone furoate, QD = once daily; SAL = salmeterol, VI = vilanterol

Back to article page

Asthma Research and Practice

ISSN: 2054-7064

Contact us